公开(公告)号：EP1893700A2

公开(公告)日：2008-03-05

申请号：EP06763402.2

申请日：2006-05-31

申请人： CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement

发明人： BUJARD, Patrice ,  STADLER, Urs, Leo ,  MAMAK, Marc ,  BUGNON, Philippe ,  REICH, Oliver

IPC分类号： C09C3/04

CPC分类号： C09C3/048 ,  A61K8/0262 ,  A61K8/19 ,  A61K8/26 ,  A61K8/29 ,  A61K2800/412 ,  A61K2800/621 ,  A61K2800/651 ,  A61Q1/02 ,  A61Q1/06 ,  A61Q1/10 ,  A61Q1/12 ,  A61Q3/02 ,  A61Q5/02 ,  A61Q19/10 ,  B22F1/0055 ,  B22F1/0085 ,  B22F2999/00 ,  C01P2002/72 ,  C01P2002/82 ,  C01P2002/84 ,  C01P2004/03 ,  C01P2006/40 ,  C09C1/0015 ,  C09C1/0021 ,  C09C2200/102 ,  B22F2202/13

摘要： The present invention relates to a process for the treatment of particles using a plasma torch and to the particles obtainable by said process. The process for the treatment of particles comprises the steps of: (A) providing particles, comprising (a) a substrate and (b) at least one layer on the substrate; or particles, especially platelet-like particles; (B) entraining said particles in a stream of gas for transport to a plasma torch; (C) creating a plasma in said stream of gas to heat the outer surface of the particles; (D) permitting said particles to cool; and (E) collecting said particles.

公开(公告)号：EP1827406A1

公开(公告)日：2007-09-05

申请号：EP05804597.2

申请日：2005-10-24

申请人： CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement

发明人： BASCHONG, Werner ,  REICH, Oliver ,  MONGIAT, Sébastien

IPC分类号： A61K31/05 ,  A61K31/222 ,  A61K31/255 ,  A61K31/34 ,  A61K31/445 ,  A61P17/00 ,  A61P17/16 ,  A61P27/14 ,  A61P29/00 ,  A61P43/00

CPC分类号： A61K31/05 ,  A61K8/11 ,  A61K8/14 ,  A61K8/347 ,  A61K8/37 ,  A61K8/375 ,  A61K8/42 ,  A61K8/46 ,  A61K8/466 ,  A61K8/4926 ,  A61K8/4966 ,  A61K8/4973 ,  A61K8/498 ,  A61K8/553 ,  A61K8/671 ,  A61K8/676 ,  A61K31/165 ,  A61K31/222 ,  A61K31/255 ,  A61K31/34 ,  A61K31/445 ,  A61K2800/412 ,  A61K2800/413 ,  A61K2800/522 ,  A61Q1/02 ,  A61Q5/02 ,  A61Q11/00 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10

摘要： Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9phenylalkyl; E is oxyl or hydroxyl; V is -O-; or -NH-; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.